The transfer of genes coding for tumor antigens (Ags) into Ag-presenting cells is a promising strategy to develop cancer vaccines for patients not limited by major histocompatibility complex restriction. To test whether autologous lymphoblastoid cell lines (LCL) can be used as an alternative to dendritic cells for Ag presentation, we established LCL by spontaneous growth in cyclosporin-containing medium in vitro (SP-LCL). SP-LCL, which have an advantage over B95-8-transfected LCL in that they carry no risk of introducing a new infectious agent when used for vaccination, served as a permanent source for transfection with an episomal Epstein-Barr virus-based expression vector encoding the Ki-ras p21 oncogene carrying a point mutation at codon 12 (muRas) as a model tumor Ag. The ability of muRas-transfected SP-LCL (muRas-LCL) to induce immunoreactivity was determined in vitro. After electroporation with an optimized protocol, muRas-LCL expressed mutated ras peptides for a considerable period of time (at least 8 weeks) on the cell surface. The transfection procedure did not affect the expression of the costimulatory molecules B7.1, intercellular adhesion molecule-1, and leukocyte function associated Ag-3 by SP-LCL. muRas-LCL were able to induce muRas-specific cytotoxic T lymphocytes from three of three healthy donors and one of one patient with pancreatic carcinoma. Our results suggest that the gene transfer of muRas sequences to SP-LCL leads to an endogenous processing of this Ag in the major histocompatibility complex class I pathway and to functional presentation of antigenic peptides to CD8 ϩ T lymphocytes. Autologous SP-LCL can serve as an unlimited renewable source for autologous cellular vaccines and appear to be good candidates as presenters for a wide range of human tumor Ags.
T he recent progress in the identification of human tumor antigens (Ag) has intensified the search for optimal cancer vaccination strategies. 1 An attractive strategy tries to induce antitumoral T-cell immunity by presentation of tumor Ags with "professional" Ag-presenting cells (APC). Different strategies using such APC are being pursued in preclinical and clinical vaccine trials. One of the most commonly used strategies is the application of APC that have been pulsed in vitro with defined peptides derived from tumor-associated Ags. 2 However, this approach requires knowledge of the human leukocyte Ag (HLA) haplotype of the donor lymphocytes as well as the restriction element of the peptide epitopes for any particular Ag. Moreover, exogenous peptide loading on major histocompatibility complex (MHC) class I molecules might be less efficient than the presentation of naturally (i.e., endogenously processed) Ag. 3 To overcome these obstacles the transfection of APC with genes encoding tumor Ags is a promising alternative that offers some advantages over peptide immunization. First, the genetically modified APC may select the appropriate epitopes using the individual's own HLA haplotype-restricted Ag-presenting machinery. Second, gene transfer to APC ensures that the gene product is endogenously processed in the MHC class I pathway. Third, usually a continuous high-level presentation of Ag is achieved.
Recent efforts toward such an approach have focused on the use of dendritic cell (DC). 4 Despite considerable progress that has been made recently in the generation of DC from human peripheral blood, the number of cells that can be obtained is still crucial, and repeated phlebotomies or leukaphereses are necessary to collect sufficient numbers of APC for clinical vaccine trials. 5 In addition to DC, macrophages and activated B cells as well as Epstein-Barr virus (EBV)-transformed Blymphoblastoid cell lines (LCL) derived from human peripheral blood B lymphocytes have been shown to be excellent professional APC. 6, 7 Although the Ag-presenting ability of LCL was initially thought to be limited to the presentation of exogenous Ags, later work demonstrated that the presentation of endogenous Ags in a MHC class I-restricted fashion is also mediated by LCL and can induce cytotoxic T lymphocytes (CTL), the major effector population of cell-mediated immune responses against tumor cells. 8 The strong expression by LCL of a variety of costimulatory molecules that can provide the second signal, which is necessary for T-cell activation, and the secretion of numerous cytokines by LCL may be an important feature that contributes to their potent immunostimulatory capacity. 9, 10 Most importantly, LCL can be easily obtained by culturing peripheral blood lymphocytes (PBL) from EBV-positive humans in vitro, because EBV-transformed B lymphocytes show a spontaneous outgrowth (SP-LCL) and can serve as a practically unlimited source of APC. 11 It was the aim of this study to determine whether and to what extent SP-LCL transfected with a tumor Ag can serve as an alternative autologous cellular vaccine for the induction of antitumoral T-cell immunity in cancer patients. To this end, SP-LCL from healthy donors and cancer patients were transfected with an episomal EBV-based expression plasmid encoding a tumor Ag.
As a model tumor Ag, we chose the point-mutated (codon 12) Ki-ras p21 oncogene (mutated Ras (muRas)). MuRas is found in a variety of malignant neoplasms, most frequently in human pancreatic cancer (ϳ90% of the cases), and has been shown previously to be specifically recognized by T cells and antibodies (Abs) from both healthy individuals and cancer patients. 12 Using an optimized protocol for the electroporation of human SP-LCL and the selection of stable Ag-expressing transfectants, we now demonstrate that muRastransfected SP-LCL display mutated ras peptides on their cell surface over a considerable period of time and are capable of eliciting strong muRas-specific CTL responses from peripheral blood mononuclear cells of healthy donors and cancer patients.
MATERIALS AND METHODS

Establishment of SP-LCL
The study was approved by the local ethical review board (Ethikkommission der Ä rztekammer des Saarlandes). Recombinant DNA work was done with the official permission and according to the rules of the State Government of Saarland. Informed consent was obtained from all healthy donors and cancer patients. SP-LCL were established by spontaneous outgrowth of PBL from EBV-seropositive donors in the presence of cyclosporin A. 11 For the establishment of these cell lines, the addition of exogenous EBV is not necessary. Briefly, 3 ϫ 10 7 peripheral blood mononuclear cells were purified by Ficoll gradient centrifugation (Pharmacia, Freiburg, Germany) and plated into 96-well plates at a density of 1 ϫ 10 6 cells/mL in RPMI 1640 (PAA Laboratories, Coelbe, Germany) supplemented with 10% fetal calf sera (FCS). Medium was exchanged once a week. After 3 weeks, cyclosporin A (Sandoz, Basel, Switzerland) was added at a final concentration of 2 g/mL. Spontaneously outgrowing B-lymphoblastoid cell clusters appeared after 21-42 days and were subcloned into several wells. Clusters from 20 wells were collected and expanded in a 25-cm 2 cell culture flask. The EBV infection of the generated cell lines was confirmed by positive immunofluorescence with monoclonal Ab (mAb) 1E6 (anti-EBV-encoded nuclear Ag (EBNA)2A/B, rat anti-human immunoglobulin G (IgG); kindly provided by Prof. N. Müller-Lantzsch, Institute of Virology, University of Saarland Medical School, Homburg, Germany). The resulting cell lines were maintained in serum-free medium (X-Vivo BioWhittaker, Verviers, Belgium).
Cell lines and Abs
SW480, a human colon carcinoma expressing mutated p21 ras (Val12) was obtained from the American Type Culture Collection (ATCC) (Manassas, Va). In cytotoxicity assays, the cell line K562 derived from an erythroleukemia (ATCC) and the HLA-A2-positive, TAP-mutant cell line T2 (174 ϫ CEM.T2; ATCC) were used as target cells. For blocking of MHC class I-restricted cytotoxicity and determination of the HLA-A2 status of the donors, the Ab BB 7.2 (anti-HLA-A2, IgG2b; kindly provided by H. G. Rammensee, Institute of Cell Biology, Tübingen, Germany) was used. Abs against CD3 (IgG1), CD4 (IgG1), CD8 (IgG1), CD80 (B7.1) (IgG1), CD54 (intercellular adhesion molecule-1 (ICAM-1)) (IgG2b), and CD58 (leukocyte function associated Ag-3 (LFA-3)) (IgG2a) were purchased from Becton Dickinson (Heidelberg, Germany).
Construction of EBV plasmids
A DNA fragment encoding amino acids 1-25 of wild-type Ki-ras or mutated Ki-ras (Val instead of Gly in codon 12) was generated by polymerase chain reaction (PCR) of two 3Ј complementary and partially overlapping 57-base primers, resulting in a primer dimer that was 97 bp in length (Fig 1) . After digestion with HindIII/BamHI, the resulting cDNA product was purified by polyacrylamide gel electrophoresis and cloned into the HindIII/BamHI sites of the expression vector pCEP4 (Invitrogen, Leek, Netherlands), resulting in pCEP4-muRas/1-25 Val12 . The expression plasmid pCEP4 contains the EBNA1 gene, the origin for plasmid replication (OriP) from EBV, and a hygromycin resistance gene and allows constitutive expression of the foreign gene under control of the human cytomegalovirus immediate-early gene enhancer-promoter. According to this method, three additional plasmids carrying the mutations Gly123 Asp12, Gly123 Arg12, and Gly123 Cys12, respectively, within the 25-aa peptide coding sequence were generated. To obtain a full-length ras gene with the mutation Gly123 Val12 (pCEP4-muRas/FL Val12 ), a cDNA encoding the 3Ј end of human H-ras was amplified by reverse transcriptase-PCR from Raji cells. The primers generated a BssHII site at the 5Ј end for in-frame insertion into the ras peptide encoding sequence, generated a BamHI site at the 3Ј end for directional cloning into pCEP4, and introduced a deletion of Cys186 of the H-ras sequence that had been shown to abrogate the transforming ability of the H-ras oncogene. 13 The correct DNA sequence of the recombinant plasmids was confirmed by DNA sequencing using Sequenase 2.0 (United States Biochemical, Braunschweig, Germany). 
Transfection of SP-LCL
Southern blot analysis
Southern blot analysis was performed according to standard protocols 15 with total cellular DNA extracted from pCEP4-muRas/1-25
Val12
-transfected SP-LCL and nontransfected SP-LCL derived from a patient with pancreatic carcinoma. After restriction enzyme treatment (EcoRI), 10 g of cleaved genomic DNA was separated by agarose gel electrophoresis and transferred onto a nylon filter (Hybond N ϩ ; Amersham, Freiburg, Germany). Hybridization with a [
32 P]deoxycytidine triphosphate-radiolabeled, HindIII-digested pCEP4-muRas/1-25
Val12 probe 15 was carried out in buffer containing 6ϫ standard saline citrate, 5ϫ Denhardt's solution, and 0.5% sodium dodecyl sulfate (SDS). Before visualization by autoradiography, the membranes were then washed at a progressively higher stringency; the final wash was in 0.1ϫ standard saline citrate and 0.1% SDS at 65°C.
Western blot analysis and immunofluorescence
Expression of the protein from the muRas sequences was confirmed by Western blot analysis and immunofluorescence staining from days 6 to 60 posttransfection. For Western blot, cell extracts were mixed with 2ϫ SDS sample buffer, electrophoresed in 12% SDS polyacrylamide gel, and blotted to nylon membranes by semidry transfer (Bio-Rad). After blocking of unspecific binding with 5% low-fat milk in tris(hydroxymeth- Figure 1 . Design of the recombinant muRas-EBV vector. In a primer dimer PCR, a cDNA fragment encoding amino acids 1-25 of wild-type or muRas was generated by two 3Ј complementary 57-base primers, resulting in a muRas minigene with a length of 97 bp. For directional cloning into the vector, a BamHI site and a HindIII site were added. The expression vector pCEP4 contains the EBNA1 gene and OriP from EBV, an expression cassette under the control of the immediate-early cytomegalovirus gene promoter, and a hygromycin resistance gene for selection in eukaryotic cells.
yl)aminomethane-buffered saline for 1 hour at 37°C, blots were incubated with an adequate dilution of a mAb specific for the mutation Gly-to-Val in position 12 of p21 ras (pan-rasVal12, mouse IgG2b; Dianova, Hamburg, Germany). Ab binding was visualized by the alkaline phosphatase/anti-alkaline phosphatase system (Bio-Rad). Immunofluorescence staining was performed according to standard protocols 16 using the mAb specific for the mutation Gly-to-Val in position 12 of p21 ras (pan-rasVal12; Dianova) and a goat anti-mouse CY3 Ab (Dianova), respectively.
Flow cytometry analysis
SP-LCL before and after transfection were tested for the expression of MHC class I molecules (HLA-A2) and the costimulatory molecules B7.1, ICAM-1, and LFA-3 by direct or indirect immunofluorescence and analyzed with a FACScan (Becton Dickinson) equipped with Lysis II software. For indirect immunofluorescence analysis, phycoerythrin-labeled goat anti-mouse mAb (Dianova) was used as a secondary Ab.
In vitro generation of CTL
PBL were plated at 5 ϫ 10 6 cells/well in 24-well plates (Nunc, Wiesbaden, Germany) and stimulated by autologous muRas-LCL every week in the presence 20 U/mL interleukin-2. For priming of naive precursor T cells, PBL were cocultured with peptide-loaded autologous DC (generated from monocytes by interleukin-4 and granulocyte-macrophage colony-stimulating factor) for 7-10 days before stimulation with muRas-LCL. After 4 weeks, the resulting T-cell bulk cultures were tested for their cytotoxic activity against different targets: autologous pCEP4-muRas/1-25
Val12 -transfected SP-LCL (muRas-LCL), autologous pCEP4-transfected SP-LCL (mock-transfected LCL), nontreated autologous SP-LCL (empty-LCL), T2 cells not loaded (empty-T2) or T2 cells loaded with peptides derived from muRas (muRas-peptide-T2) and allogenic, mismatched pCEP4-muRas/1-25
Val12 -transfected or nontreated SP-LCL. Peptides encompassing residues 5-21 of p21 ras or with a Gly-to-Val, Gly-to-Arg, Gly-to-Asp, or Gly-to-Cys substitution and a nonamer of influenza matrix protein (IMP58 -66) were purchased from Abimed (Frankfurt, Germany). For Ab blocking experiments, mAb against CD8 (Dianova) and anti-HLA-A2 (kindly provided by H. G. Rammensee) were used.
Cytotoxicity assay
T-cell bulk cultures were tested for their specific cytotoxicity in a DNA fragmentation assay (JAM test). 17 Target cells (T2 or SP-LCL) were labeled with ]thymidine-labeled target cells not loaded or loaded with the peptide of interest were then added to varying numbers of effector cells in U-bottom microwells. Each experiment was carried out at least in triplicate. After incubation for 3 hours at 37°C, all wells were harvested with a 96-well plate harvester (Wallac-Analytische Dienstleistungen, Freiburg, Germany). The radioactivity of the labeled DNA retained in the filter was measured using a scintillation ␤ counter (Wallac-ADL). Cytotoxicity was calculated as follows: Percentage of specific killing ϭ 100 Ϫ ([spontaneous retained DNA Ϫ experimental retained DNA]/[spontaneous retained DNA] ϫ 100). Spontaneous release was always Ͻ20% of the maximum release.
RESULTS
Establishment of SP-LCL
SP-LCL to be used for transfection could be established from 9 of 16 healthy individuals and 4 of 6 cancer patients. Thus, in our hands, the success rate for the establishment of autologous SP-LCL using cyclosporin A was ϳ60%. This rate is somewhat lower than the transformation rate of human B lymphocytes from the same donor samples after infection with EBV-containing supernatant of the producer cell line B95-8, which yielded LCL in 95% of the attempted cases. There was no obvious difference between the SP-LCL and the LCL generated by infection with regard to their performance in the described transfection protocol, morphology, or growth behavior.
Transfection of SP-LCL
pCEP4-muRas/1-25 Val12 , pCEP4-muRas/FL
Val12
, and pCEP4 without insert were transfected into SP-LCL from four healthy individuals and one pancreatic carcinoma patient. A number of parameters were optimized to adapt conventional electroporation protocols to the growth conditions of SP-LCL. All results shown were obtained with exponentially growing cells with a viability of 90 -100% as determined by trypan blue staining. The transfection efficiency decreased significantly when cells were used that were not in the exponential growth phase.
In a first set of experiments, we focused on the optimization of transient transfection efficiency, which is the prerequisite for obtaining high efficiencies of stable transfections. To find the optimal levels of voltage and impulse duration for electroporation, voltage was increased in 50-V steps in the range of 200 to 350 V at a capacity of 960 F and different impulse durations. A voltage of 250 V for 3 milliseconds resulted in the highest transfection efficiency: 0.5 up to 4% (mean: 1.5%) of lymphoblastoid cells were successfully transfected by pCEP4-muRas/1-25
Val12 as revealed by immunofluorescence staining with anti-muRas (Val12) Ab. The percentage of surviving lymphoblastoid cells under these transfection conditions was 50 -70% within 48 hours posttransfection (Fig 2) . To define the best electroporation medium, RPMI 1640 with and without addition of 10% (vol/vol) FCS or the electroporation buffer was used. The addition of FCS decreased the electroporation efficiency slightly. There was no obvious difference between the cell culture medium RPMI 1640 without FCS and the electroporation buffer.
A second set of experiments determined the best conditions for survival and outgrowth of successfully transfected cell clones under selective pressure with hygromycin B, which was initiated at 48 -72 hours posttransfection, depending upon the viability of the cells. To this end, 1 ϫ 10 3 transfected cells were plated into a 96-well microtiter plate in RPMI 1640 with 20% FCS supplemented with hygromycin. It was found that the detrimental effect of adding hygromycin could be weakened by starting with a low concentration of 75 g/mL hygromycin B and increasing the concentration every week up to 200 g/mL as the final concentration after 3-4 weeks. Outgrowing clones were expanded, and stable transfection efficiency was controlled by immunofluorescence staining, Western blot analysis, and Southern blot analysis (Figs 3-5) .
Optimal stable transfection efficiency was obtained by electroporation of 1 ϫ 10 7 cells in 250 L of RPMI 1640 medium with 20 g of plasmid DNA at 250 V using the gene pulser EPI 2005. Under these electroporation conditions, ϳ20 -30% of the lymphoblastoid cells from the selected cell clones expressed the muRas peptide or the mutated full-length p21 ras as demonstrated by immunofluorescence analysis and Western blot at 30 days posttransfection (Figs 3 and 4) . If the cell survival rate of 50% after the electroporation procedure is taken into account, this means a net transfection efficiency of ϳ10% of initially used lymphoblastoid cells. The transfection efficiency between cell lines from different donors varied considerably. After cotransfection of pCEP4-muRas/1-25
Val12 or pCEP4-muRas/FL Val12 and pEGFP, a similar transfection efficiency for pEGFP was determined by microscopic examination and fluorescence-activated cell sorter analysis (data not shown).
To confirm the stable transfection of SP-LCL, the presence of plasmid DNA in transfected lymphoblastoid cells was determined by Southern blot analysis at several time points after transfection (2, 4, 6, and 8 weeks). Figure 5 shows DNA of a SP-LCL-pCEP4-muRas/1-25
Val12 transfectant that was digested with EcoRI and hybridized with the 32 P-labeled pCEP4-muRas/1-25
plasmid. EcoRI digestion of pCEP4 is expected to result in three fragments with lengths of 7.5, 2.5, and 0.4 kb. Therefore, the presence of a 7.5-and a 2.5-kb band (0.4-kb band not visible) at successive timepoints indicates the continued persistence of pCEP4-muRas/1-25 Val12 in the SP-LCL transfectant. In addition, the exclusive presence of the expected two fragments of pCEP4-muRas/ Val12 in the Southern blot demonstrates the episomal state of the vector.
Using electroporation apparatus EPI 2005, which supplies a rectangle-shaped current wave, the viability of cells after transfection was significantly better compared with the results obtained with the gene pulser. This held true both for the cell survival immediately after transfection (36 -72 hours) as well as for survival after selection with hygromycin B. The higher survival rates were associated with a higher number of outgrowing hygromycin-resistant clones and resulted in a faster expansion of the transfected cells (data not shown).
Long-term expression of muRas sequences
The expression of the muRas oligonucleotides in LCL transfected with pCEP4-muRas/1-25
Val12 was detected after up to 8 weeks, when the transfected cells were subjected to immunofluorescence staining with mAb pan-rasVal12 (data not shown). From day 5 posttransfection up to day 30, the expression of the mutated p21 ras protein was also analyzed by Western blot (Fig 4) : Mutated p21 ras was found at 4 days posttransfection and reached a maximum between day 6 and day 14. After 30 days, a somewhat weaker expression was found. The expression level of the transfected ras was comparable with that of ras expressed endogenously by the human cancer cell line SW480.
Expression of immunoregulatory molecules by transfected SP-LCL
The SP-LCL 15D8 (from a healthy donor) and CO-DI.A2 (from a patient with pancreatic cancer) were analyzed for the expression of MHC class I Ags and the costimulatory molecules B7.1, ICAM-1, and LFA-3 before and after electroporation. As shown in Figure 6 , cell surface expression of these molecules by the respective SP-LCL remained stable after transfection according to our protocol.
Cytotoxicity and HLA restriction of muRas-specific CTL Stimulation with muRas-transfected SP-LCL induced a strong and specific CTL response in PBL from three of three healthy donors (Fig 7A) . The muRas-specific CTL, which were predominantly of the CD3 ϩ CD8 ϩ phenotype, were able to lyse muRas (Val12) peptide-loaded T2 cells (muRas-peptide-T2) and pCEP4-muRas/1-25 Val12 -transfected LCL (muRas-LCL). For these targets, ϳ60% specific lysis was observed (effector to target cell ratio of 40:1). The reaction could be blocked by an anti-HLA-A2 Ab or an anti-CD8 Ab, confirming the MHC class I restriction of this cytotoxic response ( Fig  7C) . Unpulsed T2 cells or T2 cells pulsed with an irrelevant peptide (IMP58 -66) were not lysed. HLA-A2-negative, mismatched muRas-transfected or untransfected LCL were also not killed (data not shown). Mock-transfected and nontransfected lymphoblastoid cells were killed in a range of 20%; this indicates that a fraction of the induced T-cell response was directed against EBV epitopes.
Stimulation of PBL from a pancreatic carcinoma patient with muRas-transfected SP-LCL demonstrated similar results (Fig 7B) . The generated muRas-specific CTL showed a specific lysis of muRas (Val12) peptideloaded T2 cells (muRas-peptide-T2) and pCEP4-muRas/1-25
Val12
-transfected LCL (muRas-LCL) in a range of 70% (effector to target cell ratio of 80:1). Unpulsed T2 cells and T2 cells pulsed with an irrelevant peptide (IMP58 -66) or mock-transfected and nontransfected lymphoblastoid cells were not lysed or were only weakly lysed. 
DISCUSSION
In search of a simple and safe delivery system of tumor Ags for specific active immunotherapy, we investigated the practicality of using SP-LCL as APC. Using a mutated form of Ki-ras as a model tumor Ag, we were able to demonstrate that stable expression of this oncogene can be achieved in SP-LCL after transfection of a mini-EBV plasmid that codes for the immunogenic region of muRas. The expression level of muRas after transfection by electroporation was comparable with the endogenous ras expression by a solid tumor cell line. Moreover, the expression of immunoregulatory molecules on the surface of these APC was not affected by the transfection procedure; finally, and most importantly, SP-LCL transfected with muRas-EBV "minigenes" were able to stimulate muRas-specific CTL from three of three healthy donors and from one pancreatic carcinoma patient, thus demonstrating the strong Ag-presenting capacity of transfected LCL. The strong induction of specific CTL responses suggests that the transfection of SP-LCL with genes encoding muRas sequences leads to an endogenous processing of this Ag in the MHC class I pathway, resulting in functional presentation of antigenic peptides to CD8 ϩ T lymphocytes. The observed CTL response against a tumor-associated Ag complements previous studies that used autologous LCL transfected with foreign genes to study Ag-specific cytotoxic T-cell responses in vitro against autoantigens 18 and viral Ags. 19, 20 However, in all of these studies, LCL were used that had been transformed by infection with exogenous EBV strains ("non-SP-LCL"), in contrast to the SP-LCL applied in this study.
The SP-LCL vaccine was specifically designed to ensure its safety. First, as the recombinant muRas-EBV vector, we chose a noninfectious and nontransforming EBV plasmid that contains only the EBV OriP and the EBV gene EBNA1. These viral elements are necessary for episomal replication and maintenance and ensure a high level of foreign gene expression in cells carrying EBV genomes (reviewed in Ref. 21); second, the engineered muRas sequence contains only the region coding for the immunogenic peptide and lacks the ras sequences responsible for the transforming capacity; third, SP-LCL derived from EBV-positive individuals were transfected. These cells, when used as gene-modified SP-LCL for vaccine trials, do not carry the risk of introducing a new infectious agent into the vaccinated patient. In contrast, EBV-LCL, which are established after in vitro transformation with infectious supernatant from the B95-8 cell line, contain an exogenous EBV. Because this virus strain is different from the strain growing in the autologous SP-LCL, a pre-existing immune response in the vaccinated patient against the exogenous EBV may be incomplete, with a consequent increased risk of a virus-associated disease, including lymphoma. 22 This is of special importance considering cancer patients are often immunosuppressed either by the tumor itself or by chemotherapy or radiotherapy. In addition, it has been reported that the B95-8 strain contains retroviral sequences that are potentially pathogenic, 23 thus raising safety and ethical concerns toward the use of B95-8-transfected LCL as a vaccine. A disadvantage of SP-LCL is the lower success rate for their establishment from PBL, which is in the range of 60% and considerably lower than the range for non-SP-LCL by infection with B95-8 supernatant; however, this problem may be overcome by repeated attempts to establish SP-LCL. Functional differences between SP-LCL and non-SP-LCL were not observed: after 8 weeks in culture, SP-LCL showed stable and rapid growth characteristics that was not different from those of non-SP-LCL and, just as importantly, displayed similar transfection rates.
In recent years, different attempts have been made to improve the stability of gene transfers into human B lymphocytes. In most cases, virus-based vectors have been employed, for example by infection of B cells with recombinant vaccinia virus 24 or by receptor-mediated endocytosis of adenovirus as a carrier for the DNA of interest. 25 In addition, replication-incompetent infectious EBV-based vectors were developed. 26 However, with regard to in vivo application as vaccines, all of these approaches include the potential hazard of working with infectious particles. In contrast, electroporation has been shown to be a safe technique for gene transfer. 27, 28 Moreover, in our experiments, electroporation turned out to be a reliable method for the stable transfection of muRas into SP-LCL. The superiority of electroporation with the EPI 2005 gene pulser compared with the Bio-Rad gene pulser is probably due to the difference in the discharge characteristics of the two systems: whereas the Bio-Rad gene pulser generates an electrical pulse with an exponential decay wave form, the EPI 2005 gene pulser delivers a rectangle-shaped current wave. This difference may have a significant impact on the initial survival rate, which is important for the successful establishment of a long-term culture of cells that stably express the transfected gene after electroporation. 29 Taken together, our results show that muRas-LCL can induce muRas-specific CTL in healthy donors and pancreatic cancer patients and hold promise as an effective tool for muRas-based active immunotherapy of patients with muRas-expressing neoplasms. This view is also supported by studies with synthetic muRas peptides that demonstrated the induction of strong cytotoxic T-cell responses against this oncogene in vitro 30 and in clinical phase I trials in vivo. 12, 31 Because recent investigations from our group demonstrated that most, if not all human cancers express multiple specific Ags, which are recognized by the autologous immune system, 32 the availability of a simple Ag presentation system such as the transfected autologous SP-LCL described here introduces the possibility of a safe and comparatively inexpensive Ag-specific active immunotherapy approach that can be offered to many patients with a wide range of human cancers.
